Opicapone

CHEMBL1089318 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

413.2 g/mol

LogP

3.4

Phase

4

A COMT inhibitor extending levodopa's effect in Parkinson's disease wearing-off episodes.

Peso molecular

413,2000 g/mol

LogP

3,40

TPSA

151,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Enfermedad de Parkinson Epilepsia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1

InChI

InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3

Molecular Formula

C15H10Cl2N4O6

HBD / HBA

2 / 8

Enlaces Rotables

2

Átomos Pesados

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A COMT inhibitor extending levodopa's effect in Parkinson's disease wearing-off episodes.

Yes, Opicapone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1089318. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135565903. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Opicapone en PillFYI

Estructura

Datos Rápidos

Fórmula: C15H10Cl2N4O6
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.